From wiki-pain
Revision as of 22:46, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.33
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 1.18
Pain Relevance 0.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (DPP4) extracellular region (DPP4) cell adhesion (DPP4)
Golgi apparatus (DPP4) endoplasmic reticulum (DPP4) plasma membrane (DPP4)
DPP4 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 23 96.50 Very High Very High Very High
headache 4 5.00 Very Low Very Low Very Low
Central nervous system 1 5.00 Very Low Very Low Very Low
tolerance 1 5.00 Very Low Very Low Very Low
cINOD 1 5.00 Very Low Very Low Very Low
adenocard 1 5.00 Very Low Very Low Very Low
Arthritis 1 5.00 Very Low Very Low Very Low
nud 1 5.00 Very Low Very Low Very Low
antagonist 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diabetes Mellitus 57 86.56 High High
Hypoglycemia 11 78.00 Quite High
Weight Loss 8 74.40 Quite High
Body Weight 8 72.24 Quite High
Disease Progression 6 69.28 Quite High
Insulin Resistance 3 62.84 Quite High
Obesity 9 61.88 Quite High
Apoptosis 1 58.08 Quite High
Disease 7 20.84 Low Low
Vomiting 10 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These comprise the injectable GLP-1 receptor agonists solely acting on the GLP-1 receptor on the one hand and orally active dipeptidyl-peptidase inhibitors (DPP-4 inhibitors) raising endogenous GLP-1 and other hormone levels by inhibiting the degrading enzyme DPP-4.
Negative_regulation (inhibiting) of Protein_catabolism (degrading) of DPP-4 associated with agonist
1) Confidence 0.33 Published 2010 Journal Pediatr Nephrol Section Abstract Doc Link PMC2874027 Disease Relevance 0.32 Pain Relevance 0.09
This structural change results in slow release from the injection site and decreased susceptibility to degradation by DPP-IV when in the circulation.
Negative_regulation (decreased) of Protein_catabolism (degradation) of DPP-IV
2) Confidence 0.22 Published 2010 Journal British Journal of Clinical Pharmacology Section Body Doc Link PMC2997321 Disease Relevance 0.86 Pain Relevance 0

General Comments

This test has worked.

Personal tools